Pluri (PLUR)
Market Price (3/30/2026): $3.2 | Market Cap: $29.6 MilSector: Health Care | Industry: Biotechnology
Pluri (PLUR)
Market Price (3/30/2026): $3.2Market Cap: $29.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 97% | Weak multi-year price returns2Y Excs Rtn is -79%, 3Y Excs Rtn is -114% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1858% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 74% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 257% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1505%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1644% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -91% | ||
| Key risksPLUR key risks include [1] a recurring risk of Nasdaq delisting and negative shareholder equity, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 97% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -79%, 3Y Excs Rtn is -114% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1858% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 74% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 257% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1505%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1644% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -91% |
| Key risksPLUR key risks include [1] a recurring risk of Nasdaq delisting and negative shareholder equity, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Pluri (PLUR) stock has lost about 15% since 11/30/2025 because of the following key factors:
1. Worsening Financial Performance and Significant Cash Burn.
Pluri experienced a notable deterioration in its financial health, reporting a net loss of $13.0 million for the six months ended December 31, 2025, an increase from $9.1 million in the prior year. Revenue remained relatively flat at $514,000 for the same period. This was accompanied by an operating cash use of $10.6 million, indicating substantial cash burn.
2. Acute Liquidity Concerns and Impending Debt Maturity.
As of December 31, 2025, Pluri's balance sheet showed a working capital deficit of $18.5 million and total cash and deposits of $13.6 million. A critical factor contributing to liquidity strain is an EIB loan with a principal of $23.5 million plus $4.3 million in accrued interest, due for repayment on June 1, 2026. Management expressed "substantial doubt" regarding the company's ability to continue as a going concern, estimating less than six months of available funding from the February 2026 reporting date.
Show more
1. Worsening Financial Performance and Significant Cash Burn.
Pluri experienced a notable deterioration in its financial health, reporting a net loss of $13.0 million for the six months ended December 31, 2025, an increase from $9.1 million in the prior year. Revenue remained relatively flat at $514,000 for the same period. This was accompanied by an operating cash use of $10.6 million, indicating substantial cash burn.
2. Acute Liquidity Concerns and Impending Debt Maturity.
As of December 31, 2025, Pluri's balance sheet showed a working capital deficit of $18.5 million and total cash and deposits of $13.6 million. A critical factor contributing to liquidity strain is an EIB loan with a principal of $23.5 million plus $4.3 million in accrued interest, due for repayment on June 1, 2026. Management expressed "substantial doubt" regarding the company's ability to continue as a going concern, estimating less than six months of available funding from the February 2026 reporting date.
Show more
Stock Movement Drivers
Fundamental Drivers
The -14.1% change in PLUR stock from 11/30/2025 to 3/29/2026 was primarily driven by a -12.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.77 | 3.24 | -14.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 1.0% |
| P/S Multiple | 25.6 | 22.4 | -12.4% |
| Shares Outstanding (Mil) | 9 | 9 | -2.9% |
| Cumulative Contribution | -14.1% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLUR | -14.1% | |
| Market (SPY) | -5.3% | 9.1% |
| Sector (XLV) | -8.7% | -8.6% |
Fundamental Drivers
The -38.5% change in PLUR stock from 8/31/2025 to 3/29/2026 was primarily driven by a -33.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.27 | 3.24 | -38.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 29.5% |
| P/S Multiple | 33.5 | 22.4 | -33.0% |
| Shares Outstanding (Mil) | 7 | 9 | -29.1% |
| Cumulative Contribution | -38.5% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLUR | -38.5% | |
| Market (SPY) | 0.6% | 13.0% |
| Sector (XLV) | 5.2% | 5.5% |
Fundamental Drivers
The -29.4% change in PLUR stock from 2/28/2025 to 3/29/2026 was primarily driven by a -40.4% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.59 | 3.24 | -29.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 97.5% |
| P/S Multiple | 37.6 | 22.4 | -40.4% |
| Shares Outstanding (Mil) | 6 | 9 | -40.0% |
| Cumulative Contribution | -29.4% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLUR | -29.4% | |
| Market (SPY) | 9.8% | 17.8% |
| Sector (XLV) | -2.1% | 11.1% |
Fundamental Drivers
The -62.1% change in PLUR stock from 2/28/2023 to 3/29/2026 was primarily driven by a -79.6% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.56 | 3.24 | -62.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 314.6% |
| P/S Multiple | 110.0 | 22.4 | -79.6% |
| Shares Outstanding (Mil) | 4 | 9 | -55.2% |
| Cumulative Contribution | -62.1% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLUR | -62.1% | |
| Market (SPY) | 69.4% | 13.7% |
| Sector (XLV) | 18.4% | 6.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PLUR Return | -79% | -36% | -38% | -8% | -30% | 8% | -94% |
| Peers Return | 11% | -21% | -0% | 42% | 11% | 12% | 55% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| PLUR Win Rate | 17% | 42% | 25% | 50% | 42% | 67% | |
| Peers Win Rate | 57% | 38% | 55% | 50% | 47% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| PLUR Max Drawdown | -79% | -54% | -53% | -10% | -31% | -2% | |
| Peers Max Drawdown | -14% | -35% | -30% | -18% | -40% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VCEL, CAPR, ALLO, TMO, TSN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | PLUR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.8% | -25.4% |
| % Gain to Breakeven | 1835.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -52.3% | -33.9% |
| % Gain to Breakeven | 109.6% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -84.0% | -19.8% |
| % Gain to Breakeven | 527.0% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -94.8% | -56.8% |
| % Gain to Breakeven | 1833.3% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to VCEL, CAPR, ALLO, TMO, TSN
In The Past
Pluri's stock fell -94.8% during the 2022 Inflation Shock from a high on 1/11/2021. A -94.8% loss requires a 1835.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Pluri (PLUR)
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
AI Analysis | Feedback
A Moderna for placental cell therapies.
AI Analysis | Feedback
- PLX-PAD: A placental expanded cell therapy product undergoing clinical trials for conditions like hip fracture recovery, COVID-19 related acute respiratory distress syndrome, and graft versus host disease.
- PLX-R18: A cell therapy product that has completed Phase I clinical trial for incomplete hematopoietic recovery and is being evaluated for treating acute radiation syndrome.
AI Analysis | Feedback
Pluristem Therapeutics Inc. (PLUR) is a biotechnology company focused on the research, development, and clinical trials of cell therapeutic products. Based on the provided description, the company's products are currently in various stages of clinical development (Phase I/II, Phase II, Phase III, and completed Phase I). There is no indication that Pluristem Therapeutics Inc. is currently selling its therapeutic products commercially to other companies or individuals.
Therefore, Pluristem Therapeutics Inc. does not have major commercial customers at this stage of its operations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Yaky Yanay, Chief Executive Officer and President
Yaky Yanay was appointed Chief Executive Officer of Pluri in June 2019, after serving as President since February 2014. Mr. Yanay has held various executive positions at Pluri since 2006, including Co-CEO, Chief Financial Officer, Chief Operating Officer, and Executive Vice President. Before joining Pluri, he served as the Chief Financial Officer of Elbit Vision Systems Ltd., a publicly traded machine vision high-tech company, and was a manager at Ernst & Young Israel. Mr. Yanay is a former Co-Chairman and current board member of Israel Advanced Technology Industries (IATI) and has founded several initiatives to support the Israeli life science industry.
Liat Zalts, Chief Financial Officer and Treasurer
Liat Zalts was appointed Chief Financial Officer and Treasurer of Pluri, effective September 30, 2024. Prior to this, she served as Pluri's Director of Finance, a position she held since December 2022. Before her tenure at Pluri, Mrs. Zalts was the CFO of Matics Manufacturing Analytics Ltd., a SaaS high-tech company. She also worked at Ernst & Young Israel (EY) from October 2008 to February 2018, where she managed audit groups for public and private companies in the high-tech sector.
Dr. Arthur Machlenkin, Chief Scientific Officer
Dr. Arthur Machlenkin joined Pluri in May 2022 as Chief Scientific Officer. He brings nearly 20 years of academic and industrial experience in drug discovery and development within the biotech industry. Dr. Machlenkin previously served as CEO at Pantheon Biosciences, an Israeli early-stage biotechnology company focused on translating bacterial immunity into antiviral platforms and therapeutics. Before Pantheon, he spent four years as Head of Immuno-Oncology (I-O) Research at Compugen.
Lior Raviv, Chief Technology Officer
Lior Raviv joined Pluri in 2011 and currently holds the position of Chief Technology Officer. His previous roles at Pluri include VP Operations & Development, Process Development Engineer, Projects Manager, and Product Development Team leader. Prior to joining Pluri, Mr. Raviv worked as an R&D Analytical Researcher at Teva Pharmaceutical Industries from 2010 to 2011.
Nofar Glaich-Dabach, Vice President of Human Resources
Nofar Glaich-Dabach leads Pluri's organizational culture and is responsible for organizational development, talent acquisition, and employee well-being. She joined Pluri's Human Resources team in 2011 as an HR Specialist and progressively advanced through various leadership roles, including Director of HR, before being appointed Vice President of Human Resources in 2025.
AI Analysis | Feedback
Key Risks to the Business:
- Failure of clinical trials and inability to obtain regulatory approval for its cell therapeutic products.
- Significant capital requirements and the challenges of commercializing novel cell therapies, including market adoption and reimbursement.
- Competition from existing and emerging treatments for the conditions Pluri targets.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Markets for Pluri (PLUR) Products:
-
PLX-PAD for Recovery after Surgery for Hip Fracture:
A direct addressable market size for therapeutic products specifically for "recovery after surgery for hip fracture" was not readily available. However, the patient population undergoing hip fracture treatment and subsequent recovery can be inferred from the hip replacement market.
- The global hip replacement market was valued at approximately USD 7.9 billion in 2024 and is projected to reach USD 11.4 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 3.9% from 2025 to 2034. North America dominated the revenue share at 50.6% in 2024.
- The global postoperative hip brace market, which supports recovery, is estimated at around USD 1.5 billion in the current year, with projections indicating it could exceed USD 2.2 billion by 2030, growing at a CAGR of approximately 5.5% to 6.5% over the next five to seven years.
-
PLX-PAD for Treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19:
- The global Acute Respiratory Distress Syndrome (ARDS) treatment market is forecast to be USD 3.81 billion in 2024 and is projected to reach USD 5.93 billion by 2032, with a CAGR of 5.7%.
- Separately, the Acute Respiratory Distress Syndrome Therapeutics Market Size across the 7 Major Markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was approximately USD 1,643 million in 2023. The US accounted for approximately 74% of this market size in 2023. This market is projected to increase at a CAGR of 3.6%.
-
PLX-PAD for Treatment of Steroid-Refractory Graft Versus Host Disease (GvHD):
- The global Graft Versus Host Disease (GvHD) treatment market was valued at USD 3.0 billion in 2021 and is estimated to reach USD 10.4 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.
- Another estimate places the global GvHD treatment market size at USD 3.08 billion in 2025, projected to grow to USD 6.34 billion by 2034, exhibiting a CAGR of 8.35%.
- In the 7MM (United States, EU4, UK, Japan), the total Graft Versus Host Disease Treatment Market Size was approximately USD 1,302 million in 2023 and is projected to increase during the forecast period of 2025–2034.
-
PLX-R18 for Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation:
- The global Hematopoietic Stem Cell Transplantation (HSCT) market was valued at USD 2.6 billion in 2022 and is expected to reach USD 6.2 billion by 2032, growing at a CAGR of 9.3%.
- Another estimate values the global HSCT market at USD 3.56 billion in 2025, expecting it to reach USD 7.48 billion by 2032, with a CAGR of 11.2%.
- North America is expected to be a dominant region in the global HSCT market, holding an estimated 33.5% market share in 2025.
-
PLX-R18 for Treatment of Acute Radiation Syndrome (ARS):
- The global acute radiation syndrome market is valued at USD 923 million in 2024 and is projected to grow to USD 1.35 billion by 2030, at a CAGR of 6.5%. The US market for ARS is estimated at USD 374.7 million in 2024, projected to reach approximately USD 513.4 million by 2030.
- Another source estimates the global Acute Radiation Syndrome Market to be valued at USD 5.47 billion in 2025 and expected to reach USD 7.80 billion by 2032, growing at a CAGR of 5.2% from 2025 to 2032.
- The broader global radiation toxicity treatment market is projected to reach USD 4.8 billion in 2026 and USD 8.3 billion by 2036. Acute radiation syndrome is anticipated to be a significant indication within this market, accounting for 35.8% of demand.
AI Analysis | Feedback
Pluri (NASDAQ: PLUR) is strategically pivoting from a clinical-stage cell therapy company to a diversified, multi-vertical biotechnology platform, with several key drivers expected to fuel its revenue growth over the next 2-3 years. Here are the expected drivers of future revenue growth for Pluri: * Expansion of Contract Development and Manufacturing Organization (CDMO) Services: Pluri is leveraging its patented 3D cell expansion technology platform to offer Contract Development and Manufacturing Organization (CDMO) services to various industries, including pharma, biologics, food-tech, and agri-tech. The company's revenue growth in fiscal year 2025 was primarily driven by increased services provided to CDMO clients, indicating a growing demand for its manufacturing capabilities for cell-based products. * Commercialization of Food-Tech and Agri-Tech Ventures: Pluri has established joint ventures in the food-tech sector, notably Ever After Foods for cultivated meat products and Coffeesai Ltd. for cell-based coffee. These initiatives represent a significant business model transformation aimed at pioneering sustainable food solutions, and their commercial success is crucial for the company's future revenue trajectory. * Advancement and Potential Commercialization of Immunotherapy Platform: The company is developing an allogeneic Mucosal-Associated Invariant T (MAIT) cell therapy platform, derived from the human placenta, for applications in immunotherapy, particularly for solid tumors. This platform is designed to enable Chimeric Antigen Receptors (CAR) to reach tumors, potentially leading to improved infiltration and efficacy in cancer treatment, an area currently lacking approved cell-based therapies. * Progress and Market Entry of Core PLX-PAD and PLX-R18 Cell Therapies: Despite diversification, the advancement of Pluri's core cell therapy product candidates, PLX-PAD and PLX-R18, remains a potential revenue driver. PLX-PAD is in Phase III clinical trials for hip fracture recovery, Phase II for acute respiratory distress syndrome associated with COVID-19, and Phase I/II for steroid-refractory graft versus host disease [cite: BACKGROUND, 2]. PLX-R18 has completed Phase I for incomplete hematopoietic recovery following hematopoietic cell transplantation [cite: BACKGROUND, 2]. Successful completion of these clinical trials and subsequent market approvals would allow Pluri to commercialize these therapies.AI Analysis | Feedback
Share Issuance
- In February 2021, Pluri (then Pluristem Therapeutics Inc.) completed a registered direct offering to institutional investors, issuing 4,761,905 shares of common stock at a price of $6.30 per share, resulting in gross proceeds of $30 million.
- Effective April 1, 2024, the company implemented a 1-for-8 reverse share split, reducing its outstanding common shares from approximately 41.8 million to about 5.2 million, and proportionally decreasing authorized capital shares from 300 million to 37.5 million.
- In May 2020, Pluristem Therapeutics Inc. completed a registered direct offering to institutional investors, issuing 1,587,302 shares of common stock at $9.45 per share, with net proceeds expected to be approximately $15 million.
Inbound Investments
- In May 2021, Pluri received €20 million (approximately $24 million) from the European Investment Bank (EIB) as the first tranche of a €50 million non-dilutive financing agreement.
- The proceeds from the EIB funding were designated to support research and development (R&D) activities in the European Union to advance Pluri's proprietary regenerative cell therapy platform.
Outbound Investments
- In November 2021, Pluri established Ever After Foods Ltd., a subsidiary in Israel focused on cultivated meat products, in which Pluri Biotech holds approximately 69% equity.
- In June 2024, Pluri invested $1.25 million in a private placement offering for Ever After Foods, which raised an aggregate of $10 million from strategic investors including Tnuva.
- In April 2025, Pluri completed the acquisition of approximately 79% of the equity in Kokomodo Ltd., an Israeli startup dedicated to developing cultivated cacao production.
Capital Expenditures
- Proceeds from a May 2020 registered direct offering were intended for working capital, funding clinical studies, and investment in capital equipment, among other general corporate purposes.
- The €20 million non-dilutive funding received from the European Investment Bank in May 2021 was aimed at supporting research and development (R&D) in the European Union to advance the company's regenerative cell therapy platform.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can Pluri Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to PLUR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 29.12 |
| Mkt Cap | 1.4 |
| Rev LTM | 139 |
| Op Inc LTM | -7 |
| FCF LTM | 1 |
| FCF 3Y Avg | -5 |
| CFO LTM | 16 |
| CFO 3Y Avg | 15 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.4% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 7.0% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | 3.1% |
| Op Mgn 3Y Avg | 1.4% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 10.6% |
| CFO/Rev 3Y Avg | 11.6% |
| FCF/Rev LTM | 5.5% |
| FCF/Rev 3Y Avg | 2.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.4 |
| P/S | 4.7 |
| P/EBIT | 9.6 |
| P/E | 12.6 |
| P/CFO | 4.7 |
| Total Yield | -3.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.9% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.5% |
| 3M Rtn | 0.8% |
| 6M Rtn | 11.1% |
| 12M Rtn | 0.6% |
| 3Y Rtn | -5.6% |
| 1M Excs Rtn | -2.5% |
| 3M Excs Rtn | 7.3% |
| 6M Excs Rtn | 15.7% |
| 12M Excs Rtn | -11.5% |
| 3Y Excs Rtn | -66.8% |
Price Behavior
Price Behavior
| Market Price | $3.24 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -52.0% | |
| 50 Days | 200 Days | |
| DMA Price | $3.42 | $4.10 |
| DMA Trend | down | up |
| Distance from DMA | -5.3% | -21.0% |
| 3M | 1YR | |
| Volatility | 61.2% | 90.6% |
| Downside Capture | 0.31 | 1.03 |
| Upside Capture | 96.93 | 88.00 |
| Correlation (SPY) | 7.8% | 17.3% |
PLUR Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.09 | -0.17 | 0.41 | 0.82 | 0.80 | 0.71 |
| Up Beta | -4.06 | -3.33 | -0.38 | 1.52 | 0.57 | 0.20 |
| Down Beta | -1.63 | 0.85 | 0.65 | 0.33 | 0.73 | 0.78 |
| Up Capture | 48% | 96% | 31% | 16% | 72% | 37% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 19 | 25 | 51 | 103 | 337 |
| Down Capture | -77% | -54% | 66% | 136% | 115% | 106% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 9 | 17 | 31 | 67 | 138 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PLUR | |
|---|---|---|---|---|
| PLUR | -32.8% | 90.3% | -0.07 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 11.1% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 17.7% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -0.4% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -1.9% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 12.2% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 7.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PLUR | |
|---|---|---|---|---|
| PLUR | -40.9% | 75.8% | -0.37 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 10.7% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 18.4% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 2.1% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 2.8% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 12.4% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 8.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PLUR | |
|---|---|---|---|---|
| PLUR | -30.7% | 73.5% | -0.18 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 17.2% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 20.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 2.9% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 7.0% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 13.6% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/12/2026 | 10-Q |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 09/17/2025 | 10-K |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/11/2025 | 10-Q |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/18/2024 | 10-K |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/12/2024 | 10-Q |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 09/12/2023 | 10-K |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-Q |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 09/21/2022 | 10-K |
| 03/31/2022 | 05/09/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Manieu, Alexandre Weinstein | Shares indirectly held through Plantae Bioscience Ltd. | Buy | 11202025 | 4.61 | 452,702 | 2,086,956 | 2,086,956 | Form | |
| 2 | Manieu, Alexandre Weinstein | Shares indirectly held through Chutzpah Holdings Limited | Buy | 7012025 | 4.61 | 523,437 | 2,413,045 | 4,293,044 | Form | |
| 3 | Manieu, Alexandre Weinstein | Shares indirectly held through Plantae Bioscience Ltd. | Buy | 7012025 | 4.61 | 452,702 | 2,086,956 | 2,086,956 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.